Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Lokhorst HM, et al. Among authors: breitkreutz i. Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644. Haematologica. 2008. PMID: 18166796 Free article. Clinical Trial.
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, Benner A, Glasmacher A, Schmidt-Wolf IG, Martin H, Hoelzer D, Ho AD, Lokhorst HM; HOVON; GMMG. Goldschmidt H, et al. Among authors: breitkreutz i. Ann Hematol. 2003 Oct;82(10):654-9. doi: 10.1007/s00277-003-0685-2. Epub 2003 Jul 4. Ann Hematol. 2003. PMID: 12845480 Clinical Trial. No abstract available.
[First-line treatment of multiple myeloma].
Breitkreutz I, Raab M, Goldschmidt H. Breitkreutz I, et al. Internist (Berl). 2019 Jan;60(1):23-33. doi: 10.1007/s00108-018-0527-x. Internist (Berl). 2019. PMID: 30552458 Review. German.
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AM, Westveer PH, Sonneveld P, Goldschmidt H, Lokhorst HM. Minnema MC, et al. Among authors: breitkreutz i. Leukemia. 2004 Dec;18(12):2044-6. doi: 10.1038/sj.leu.2403533. Leukemia. 2004. PMID: 15470485 Clinical Trial. No abstract available.
[Erratum to: First-line treatment of multiple myeloma].
Breitkreutz I, Raab M, Goldschmidt H. Breitkreutz I, et al. Internist (Berl). 2019 May;60(5):552. doi: 10.1007/s00108-019-0581-z. Internist (Berl). 2019. PMID: 30887073 German. No abstract available.
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.
Baertsch MA, Fougereau M, Hielscher T, Sauer S, Breitkreutz I, Jordan K, Müller-Tidow C, Goldschmidt H, Raab MS, Hillengass J, Giesen N. Baertsch MA, et al. Among authors: breitkreutz i. Cancers (Basel). 2021 Sep 20;13(18):4706. doi: 10.3390/cancers13184706. Cancers (Basel). 2021. PMID: 34572934 Free PMC article.
27 results